The problem of a randomized controlled trial is that it doesn’t explain mechanism or pertain to individual subjects
Compared with the placebo group and assuming 100 base pair erosion per year, we can say that the low-dose TA-65 group GAINED SEVEN YEARS of viable telomere length.
DISCLAIMER: This website is for educational purposes only and is not for advertising. Telomerase activators and nanovesicles are not FDA-approved to prevent or treat any disease and anecdotes are not scientific proof of efficacy. All patients were treated in the context of a fully informed and legally-protected patient physician relationship.
Required fields
© 2020 Recharge Biomedical
Exosomes and TA-65 are not FDA-approved to prevent or treat any illness
